Xvivo Perfusion AB (LTS:0RKL) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKL Xvivo Perfusion AB LTS:0RKL
84 GF Score
Price kr235.11
GF Value kr397.30
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0RKL
84GF Score
Xvivo Perfusion AB LTS:0RKL
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xvivo Perfusion AB (LTS:0RKL) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of kr235.11 is trading 40.8% below its estimated GF Value™ of kr397.30. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for LTS:0RKL:

  • FFO:
  • GF Value™: kr397.30 vs. price of kr235.11 (40.8% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RKL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
84GF Score

Get the complete analysis for LTS:0RKL

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr235.11
Price
kr397.30
GF Value